|  |
| --- |
| **eMERGE Network: Manuscript Concept Sheet** |
| **Reference Number** *(to be assigned by CC)* | NT444 |
| **Submission Date** | 3/21/22 |
| **Project Title** | Lessons learned from eMERGE about impact on patients and providers |
| **Tentative Lead Investigator** *(first author)* | Ellen Wright Clayton |
| **Tentative Senior Author** *(last author)* |  |
| **All Other Authors**  | Maureen Smith, Malia Fullerton, Ingrid Holm, Anna Lewis |
| **Sites Participating** | VUMC, NU, UW, BCH |
| **Background / Significance** | Over the course of the eMERGE consortium, there has been a lot of discussion and evolution about whether and what results to return, made more complex by the pressure to merge research and clinical care and the growing importance of translational research, and how best to do so. In the process, much has been learned about implementation. |
| **Outline of Project** | Review of prior article and summarize lessons learned with guidance for future |
| **Desired Data - Common Variables\*** *(Available from the CC)* | [ ]  Demographics [ ]  ICD9/10 codes[ ]  CPT codes[ ]  Phecodes[ ]  BMI | [ ]  Common Variable Labs[ ]  Common Variable Meds[ ]  Other: Case/Control status on Phase I [ ]  and Phase II phenotypes |
| **Other Desired Data *(Available from participating sites)*** | *Please specifically list out any data elements that participating sites would collect or extract from clinical or other sources for this project (i.e. not common variables above)*  |
| **Desired Genetic Data** | [ ]  eMERGE I-III Merged set (HRC imputed, GWAS)[ ]  eMERGE PGx/PGRNseq data set [ ]  eMERGEseq data set (Phase III)[ ]  eMERGE Whole Genome sequencing data set[ ]  eMERGE Exome chip data set[ ]  eMERGE Whole Exome sequencing data set[ ]  Other (not listed above): |
| **Does project pertain to an existing eMERGE Phenotype?** | [ ]  Yes, if so please list [x]  No |
| **Planned Statistical Analyses** |  |
| **Ethical Considerations** |  |
| **Target Journal** |  |
| **Milestones***(This section should include the key dates for completion of project, including approval, project duration, draft completion, and submission.)* | Draft finished: May 2022Submit to journal: July 2022 |

**\*Common Variables available across all datasets:**

* Demographics: sex, year of birth, decade of birth, race, ethnicity
* Codes: (repeated values & age at event): ICD, CPT, Phecodes
* BMI: (repeated value & age at event) height, weight, BMI
* Labs: (lab name, repeated lab value & age at event) Serum total cholesterol, LDL, HDL, Triglycerides, Glucose fasting/non-fasting/unknown, & White Blood Cell count
* Medications: (medication name, repeated, & age at event) Cerivastatin sodium, Rosuvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin, Atorvastatin, & Pitavastatin
* Other: Case/Control status on Phase I and Phase II phenotype: only on GWAS dataset participants